Orphan Therapy Opportunity Vybion’s lead program INT41 targets Huntington’s disease and has Orphan Disease Designation with an IND enabling path defined, offering a potential near-term collaboration or grant-funded development partnership opportunities with specialty pharma players or academic consortia focused on neurodegenerative therapies.

Intranasal Delivery Focus The company intends to use intranasal delivery of loaded exosomes for gene therapy, signaling a potential for CROs and contract manufacturers with expertise in CNS delivery, exosome technologies, or specialized formulation development to support preclinical and IND-enabling studies.

Intrabody Platform INT41 represents a novel intrabody approach to block toxic polyQ protein function, suggesting sales opportunities in partnering with gene therapy and antibody engineering service providers, as well as contract research organizations skilled in protein design, validation, and toxicology.

Funding and Scale With modest revenue historically reported and a small team, Vybion may pursue strategic collaborations, licensing, or co-development deals with larger biotechs or CROs to scale preclinical assets, attract investment, and accelerate IND timelines.

Technology and Ops Fit Existing tech stack and cloud hosting indicate readiness for partnered translational work; targeted outreach to web/apply-focused vendors, regulatory affairs consultants, and preclinical logistics providers could support data management, regulatory packaging, and IND prep services.